文献速递免疫规划妇幼与学校卫生

青春期女性按标准或延长间隔接种两剂或三剂四价人乳头瘤病毒疫苗的抗体应答

Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.
PubMed 文献 · Vaccine · 2018-01-03

多中心前瞻性研究纳入1321名9-17岁女孩,在接种第三剂4vHPV当日或28天内入组,比较第二、三剂按时或显著延迟接种后1个月和6个月抗体滴度。第三剂后1个月GMT各延迟组不劣于按时组,第二剂显著延迟组更优;6个月时多数基因型GMT延迟组更优。延长间隔似乎不削弱、甚至可能增强抗体应答。

要点

  • 第三剂后1个月GMT在延迟组2、3、4不劣于按时组,组2更优
  • 第三剂后6个月GMT除组3的HPV18外各延迟组均更优
  • 第二剂显著延迟时第二剂后滴度显著高于按时接种的第二剂后滴度

核心结论

  • 延长各剂次间隔似乎不削弱、甚至可能增强对4vHPV的抗体应答。

研究设计与样本

  • 多中心前瞻性研究纳入1321名9-17岁健康女孩,在第三剂4vHPV接种当日或28天内入组。
  • 按第二、三剂是否按时分为对照组、组2(第二剂按时、第三剂显著延迟)、组3(第二剂显著延迟、第三剂按时)、组4(两剂均显著延迟)。

主要发现

  • 第三剂后1个月GMT:与按时接种相比,组2、3、4不劣于按时组,组2更优。
  • 第三剂后6个月GMT:除组3的HPV18外,组2、3、4各基因型均更优。
  • 第二剂按时接种时,年龄调整的第二剂后滴度显著低于第三剂后滴度;第二剂显著延迟时,第二剂后滴度显著高于第三剂后滴度。
  • 第二剂显著延迟时,≥15岁与<15岁参与者的第二剂后滴度无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The originally recommended dosing schedule, 0, 2, 6 months, for the 3-dose quadrivalent human papillomavirus vaccine (4vHPV) was often not followed, resulting in longer than recommended intervals between doses and interest in the effect of prolonged intervals. Recent two-dose recommendations require investigations into the effect of delaying dose 2. METHODS: This multi-site, prospective study enrolled healthy 9-17 year old girls (n = 1321) on the day of or within 28 days following a third dose of 4vHPV vaccination. Antibody titers to 4vHPV types were measured at one and six months post-dose 3 from all participants and post-dose 2 from participants who were on time for dose 3. To compare antibody responses, participants were categorized into groups: second and third doses on time (control group); on-time dose 2, substantially late dose 3 (group 2); substantially late dose 2, on-time dose 3 (group 3); both doses substantially late (group 4). Analyses compared age-adjusted geometric mean titers (GMTs) at one-month and six-months post-dose 3, effect of delaying the second dose, and two versus three doses as well as post-dose 2 GMTs, stratified by age. RESULTS: Compared to on-time dosing, one-month post-dose 3 GMTs were non-inferior in groups 2, 3, and 4 and were superior in group 2. Six month post-dose 3 GMTs were superior in groups 2, 3, and 4 for each genotype, except HPV 18 in group 3. Age-adjusted post does 2 titers were significantly lower than post-dose 3 titers when dose 2 was on time but were significantly higher when dose 2 was substantially late. Participants ≥15 years old had no difference in post-dose 2 titers compared to <15 year olds when dose 2 was substantially delayed. CONCLUSIONS: Prolonged intervals between doses do not appear to diminish and may enhance antibody response to 4vHPV. ClinicalTrials.gov (NCT00524745).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Widdice LE, Unger ER, Panicker G, et al. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. 2018. PMID: 29306506. doi:10.1016/j.vaccine.2017.12.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。